41 results about "Opioid addiction" patented technology

Embodiments include methods of determining a patient's susceptibility (i.e., risk) of becoming dependent and / or addicted to an addictive substance. The addictive substance can be an opioid receptor agonist. In aspects, the methods include use of a lateral flow assay (LFA) test with up converting phosphors (UCPs). If a patient is deemed susceptible to addiction, a monitoring / dispensing system can be used to administer the addictive substance (e.g., opioid receptor agonist).

Disclosed herein are immune activating conjugates with immunogenic carrier proteins coupled to hapten and immune cell receptor agonist-containing polymers. The polymers promote uptake by B cells, enabling intracellular immune cell receptor activation and formation of long-lived antibody-secreting cells. In some aspects, disclosed herein in is a conjugate comprising an immunogenic carrier protein coupled to a polymer, wherein the polymer includes: i) a first monomeric unit comprising a first monomer coupled to a hapten, and ii) a second monomeric unit comprising a second monomer coupled to an immune cell receptor agonist.

A series of non-peptide mu opioid receptor (MOR) selective modulators is provided. The compounds have the general formula (I) where R is (II) and where one of a, b, c, d, e or f is the point of attachment of indole ring R to the epoxymorphinan skeleton; at least one of the atoms at positions a, b, c, d, e and f is N; the remaining atoms at positions at a, b, c, d, e and f are CH; and * is a chiral carbon. The compounds are generally MOR antagonists and are used to treat disorders related to opioid receptor functions such as opioid addiction and opioid overdose, for the treatment of neurological diseases and for the treatment of pain, without causing constipation.

A compound having a structure of formula (I), (II), (III), (IV), (V), (VI), or a pharmaceutically acceptable salt, a tautomer, or a solvate thereof for use in treating opioid addiction, withdrawal and / or dependence and / or loss of opioid induced analgesia and / or occurrence of opioid induced hyperalgesia in a subject in need thereof.

The present disclosure provides a pharmaceutical composition comprising buprenorphine, a derivative thereof, or a pharmaceutically acceptable salt thereof, a stabilizer, a biocompatible solvent, and at least one compound represented by Formula (IIA), Formula (IIB), or Formula (IIC) wherein R1 is hydrogen, C1-C20 alkylcarbonyl, or C6-C18 arylcarbonyl, and wherein within the shelf life of the pharmaceutical composition, R1 is hydrogen, C1-C20 alkylcarbonyl, or C6-C18 arylcarbonyl, R2 is hydrogen, C1-C20 alkylcarbonyl, or C6-C18 arylcarbonyl, and R3 is hydrogen, C1-C20 alkylcarbonyl, or C6-C18 arylcarbonyl. The amounts of the compounds of formula (IIA), formula (IB), and formula (IIC) are each less than 1% w / w based on the total weight of the pharmaceutical composition. The disclosure also provides a method of making the pharmaceutical composition and a method of administering the pharmaceutical composition to a subject in need thereof to treat opioid addiction, pain, and / or depression. # imgabs0 #

A method comprises acquiring a plurality of multimodal physiological signals, dividing the plurality of multimodal physiological signals into a plurality of sliding windows containing a respective multimodal physiological signal, selecting a subset of the plurality of sliding windows that contain the respective multimodal physiological signal, modifying the respective multimodal physiological signal contained in the subset of the plurality of sliding windows; providing, as one or more inputs to a machine learning model, the plurality of sliding windows that contain the respective multimodal physiological signal and the subset of the plurality of sliding windows that contain the respective modified multimodal physiological signal; and identifying, using one or more outputs of the machine learning model, at least one moment of opioid administration.

The invention provides application of dexmedetomidine in preparation of a medicine for promoting morphine addiction fading, and relates to the technical field of opioid medicine addiction fading. According to the application, it is found for the first time that dexmedetomidine can play a new role in promoting regression of addiction, and clinical application of dexmedetomidine is improved. Dexmedetomidine is widely applied clinically, no related research shows that addiction can be caused by long-time use of dexmedetomidine at present, the effect of promoting the fading of morphine addiction of mice by adopting dexmedetomidine can generate a remarkable effect in a short time, no obvious adverse reaction is seen, and the application has the characteristics of safety and feasibility. Dexmedetomidine is convenient and rapid to administrate and good in compliance, and has very strong clinical applicability in the aspect of promoting morphine addiction fading.

A system for dispensing prepackaged single doses of a medication. The system includes a carousel made up of columns each containing single doses sharing a dosage size and a medication type, configured to rotate about an axis. A pushing mechanism is coupled to the columns, configured to push a selected single dose from a column onto the verification platform. The system further includes a biometric authentication mechanism for determining an identity of a patient based on biometric data to find a dosage order corresponding to their identity, and directing the rotation mechanism to rotate the dose in the dosage order in-line with the pushing mechanism. The system further includes a mechanism configured to dispense the selected single dose if the selected single dose matches the dosage order, and push the selected single dose into a rejection reservoir if the selected single dose does not match the dosage order.

The present disclosure provides methods and compositions for reducing the addictive liability of opioid analgesics in a subject, for example, by co-administering to the subject the opioid and a serotonin receptor type 2 (5HT2) agonist or a serotonin (5HT) releasing agent. The disclosed methods include methods for preventing opioid abuse, methods for reducing the rewarding effect of an opioid, methods for reducing the addictive liability of an opioid, methods for eliminating or substantially reducing the tendency for a subject to develop physical dependence, tolerance, and / or withdrawal symptoms with respect to an opioid, and methods for eliminating or substantially reducing the tendency for a subject to use opioids in ways not prescribed, take opioids more often or in larger amounts than prescribed, and / or use opioids recreationally. The methods can be performed on a subject, such as a patient (e.g., a human patient).

The present invention provides methods for treating and / or managing pain. The invention further provides methods for reducing or inhibiting opioid tolerance, reducing risk of opioid addiction or dependence, restoring opioid efficacy, and enhancing the therapeutic effect of an opioid. The invention further provides compositions for use in the methods of the invention.

Provided is a pharmaceutical composition including buprenorphine, a derivative thereof, or a pharmaceutically acceptable salt thereof, a stabilizer, a biocompatible solvent, and at least one compound represented by Formula (IIA), (IIB) or (IIC), wherein R1 is hydrogen, a C1-C20 alkylcarbonyl group, or a C6-C18 arylcarbonyl group, and wherein the compound of Formula (IIA), (IIB) and (IIC) each have an amount of less than 1% w / w based on the total weight of the pharmaceutical composition during a shelf life of the pharmaceutical composition. Also provided is a method for preparing the pharmaceutical composition and a method for treating opioid addiction, pain, and / or depression in a subject in need thereof by administering the pharmaceutical composition to the subject.

Provided is a chiral cannabidiol (CBD) derivative drug, comprising four chiral derivatives, i.e., (7S)-(-)-CIAC001, (7R)-(-)-CIAC001, (7S)-(+)-CIAC001, and (7R)-(+)-CIAC001; and a use of the four chiral derivatives of CBD in the treatment of neuroinflammation and opioid addiction. Also disclosed are anti-neuroinflammation effects and the ability to regulate the activity of pyruvate kinase M2 (PKM2) of CBD analogs.

The present disclosure relates to cannabinoid-based therapeutics, and their use in treating pain, e.g., chronic pain. The present disclosure also relates to cannabinoid-based therapeutics, and their use in treating opioid addiction.

The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. The compound of Formula (I) is used as hapten and is useful as an antigen in a vaccine for a disease, (e.g., opioid addiction). Also provided in the present disclosure are vaccines, pharmaceutical compositions, kits, methods, and uses including or using compounds of Formula (I) and compositions comprising compounds of Formula (I).

The present disclosure relates to cannabinoid-based therapeutics, and their use in treating pain, e.g., chronic pain. The present disclosure also relates to cannabinoid-based therapeutics, and their use in treating opioid addiction.

A series of non-peptide opioid receptor modulators having the general formula: (I) is provided. In the formula: R=(II) * is a chiral carbon; M is a saturated or unsaturated, branched or unbranched, substituted or unsubstituted alkyl chain from 0-10 atoms in length; X1, X2, X3, X4, or X5 are independently, C, N, O, or S; and R is attached to M by any of X1, X2, X3, X4, or X5. The compounds are used to treat disorders related to opioid receptor functions such as opioid addiction, opioid overdose, pain and constipation caused by opioid use.

CBD derivatives effective for treating opioid addiction, neurodegenerative diseases and neuroinflammation. The CBD derivatives have lower toxicity than CBD, are not addictive, and do not inhibit respiration or damage short-time memory.

A device for automated pumping and dispensing of single doses of opioid addiction medication to a user. The device includes a pumping platform, an outlet, and a cup dispensing component configured to dispense a cup onto the pumping platform. The device further includes a pumping mechanism configured to rotate and pump the opioid addiction medication into the cup. The device further includes a pusher wheel operatively coupled to the pumping platform, configured to cyclically rotate between positions. In one position, the pusher wheel pushes the pumping mechanism away and blocks the outlet. In another position, the pusher wheel moves such that the pumping mechanism rotates over the pumping platform and blocks the outlet. In another position, the pusher wheel pushes the cup from the pumping platform to the outlet and moves such that the outlet is exposed.

Provided herein are vaccine compositions comprising a hapten-conjugated to a capsid, wherein the capsid comprises wild type or native sequence, or at least one mutation. Also provided herein are vaccine compositions comprising a hapten conjugated to a capsid, wherein said capsid comprises at least one mutation, such as a non-natural mutation. Such compositions are useful in the treatment and / or prevention of opioid use disorders (OUDs), including opioid addiction and opioid overdose across a broad spectrum of opioids.

The disclosure relates to pharmaceutical composition comprising dopamine antagonists and methods of using the same to treat pain, prevent drug liking and opioid addiction.

Disclosed are methods and compositions comprising fibroblasts and / or products derived thereof for the inhibition and / or treatment of addiction of any kind, such as opioid addiction. In some embodiments, methods comprise treating a patient addicted to opioids by administering a fibroblast population at a concentration sufficient for suppression of addiction-associated brain damage. In some embodiments, the fibroblasts express CD31 and / or CD73 markers. In some embodiments, fibroblasts are used to endow neuronal regeneration in order to overcome changes in the brain associated with addiction. Some embodiments relate to the stimulation of hippocampal regeneration subsequent to addiction induced damage.

The present invention relates to a composition for detecting an opioid-based drug, the composition comprising an opioid receptor nanodisc. Specifically, the opioid receptor nanodisc according to the present invention detetcs an opioid-based drug with high sensitivity and selectivity, and thus may find useful application in diagnosing opioid-based drug addiction or detecting an opioid-based drug.

The present application includes mitragynine analogues of Formula la or lb, compositions comprising said compounds and uses thereof, for example for treating and managing pain, for treating neurological or psychiatric diseases and disorders, for example treating an opioid addiction or opioid withdrawal symptoms.

The present disclosure provides methods of predicting, quantifying, and / or treating high-risk opioid addiction.

A method for remotely approving and dispensing medications directly to a patient for opioid addiction treatment. The method includes determining an identity of the patient, by a biometric sensing component and establishing remote communication between the patient and a medical official certified for treating opioid addiction. The method also includes transmitting a medical record corresponding to the patient to the medical official, generating, by the medical official, the opioid addiction treatment, generating an event record made up of the identity of the patient, the opioid addiction treatment, the medical record, and the medical official, and transmitting the event record to a dosing location.

The present disclosure is directed to embodiments of a kiosk including a chassis having a patient compartment and a medication compartment. A patient does not have access to the medication compartment in the patient compartment. A dispense structure extends from the patient compartment to the medication compartment such that a dosage of medication may be dispensed to the patient when within the patient compartment. After the medication is dispensed to the patient, a medical professional observes the patient ingest the medication through a video conference display within the patient compartment. A biometric scanner may be in electrical communication with a lock in mechanical cooperation with a door hingedly coupled to the chassis to limit access to the medication compartment. An insulated safe with an internal chamber wherein the internal chamber's temperature is regulated. A medication is stored within the internal chamber of the insulated safe at a selected temperature by regulating the temperature within the internal chamber of the insulated safe.

A device for automated pumping and dispensing of single doses of opioid addiction medication to a user. The device includes a pumping platform, an outlet, and a cup dispensing component configured to dispense a cup onto the pumping platform. The device further includes a pumping mechanism configured to rotate and pump the opioid addiction medication into the cup. The device further includes a pusher wheel operatively coupled to the pumping platform, configured to cyclically rotate between positions. In one position, the pusher wheel pushes the pumping mechanism away and blocks the outlet. In another position, the pusher wheel moves such that the pumping mechanism rotates over the pumping platform and blocks the outlet. In another position, the pusher wheel pushes the cup from the pumping platform to the outlet and moves such that the outlet is exposed.

Compounds and methods for modulating the activity of receptors are disclosed. Some of the compounds modulate the activity of glycine receptors. Certain embodiments of the compounds are useful for treatment of pain, treatment of opioid addiction, and / or reduction of side effects attributable to opioid use.